<DOC>
	<DOCNO>NCT00058773</DOCNO>
	<brief_summary>Subjects type lymph gland cancer call Hodgkin non-Hodgkin Lymphoma , come back go away treatment , include best treatment know relapse Lymphoma . We ask subject volunteer research study use Epstein Barr virus ( EBV ) specific cytotoxic T lymphocytes , new experimental therapy . This therapy never use patient Hodgkin disease type non-Hodgkin Lymphoma use successfully child type blood cancer cause EBV bone marrow transplantation . Some patient Hodgkin disease non-Hodgkin Lymphoma show evidence infection virus cause infectious mononucleosis Epstein Barr virus ( EBV ) time diagnosis Lymphoma . EBV often find cancer cell suggest may play role cause Lymphoma . The cancer cell infect EBV clever able hide body 's immune system escape destruction . We want see grow special white blood cell , call T cell , train kill EBV infected cell give back subject .</brief_summary>
	<brief_title>Giving Gene Marked EBV Specific T-Cells Patients Receiving BMT Relapsed EBV-Positive Hodgkin Disease</brief_title>
	<detailed_description>We take 60-70 ml ( 12 teaspoonful ) blood subject . We first make B cell line call lymphoblastoid cell line LCL infect subject blood laboratory strain EBV call B95 . We use use EBV infect cell line ( treated radiation grow ) stimulator cell mix blood . This stimulation train T cell kill EBV infect cell result growth EBV specific T cell line . We test T cell make sure kill EBV infected cell normal cell freeze . The cell thaw injected subject 10 minute , pretreatment Tylenol Benadryl . A total two dos give two week apart . All treatment give Texas Children 's Hospital The Methodist Hospital . We follow subject clinic injection . At visit 10ml ( 2 teaspoonful ) blood take every week 6 week injection every 3 month 1 year monitor subject blood chemistry hematology . To learn way T cell work subject body , extra 40mls ( 8 teaspoon ) blood take pre-infusion , 3-4 day post infusion ( optional ) 1 , 2 , 4 6 week post-infusion 3 , 6 , 9 , 12 month . The blood may draw subject central line time regular blood test .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Any patient Hodgkin disease nonHodgkin Lymphoma , contain EBV genome antigen , receive autologous bone marrow transplant regardless age sex . Patients tumor tissue EBV +ve . Patients life expectancy &gt; 6 week . Patients Karnofsky score &gt; 50 . No severe intercurrent infection . Patient , parent/guardian able give inform consent . Patient Bilirubin &lt; 2x normal , SGOT &lt; 3x normal , ANC great 500mm Patients creatinine &lt; 2x normal age creatinine clearance &gt; 2x normal age . Patients investigational therapy one month prior entry study . EXCLUSION CRITERIA : Patients life expectancy &lt; 6 week . Patients EBV positive Lymphoma secondary acquire congenital immunodeficiency . Patients Karnofsky score less equal 50 . Patients severe intercurrent infection . Patients bilirubin &gt; 2x normal , SGOT &gt; 3x normal , abnormal prothrombin time . Patients creatinine &gt; 2x normal age creatinine clearance &lt; 2x normal age . Patients ANC &lt; 500mm Patient , parent/guardian unable give inform consent . Patients investigational therapy within one month prior entry study . Due unknown effect therapy fetus , pregnant woman exclude research . Women childbearing potential must appropriate birth control duration study 6 month completion study . In addition , male partner use condom .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Hodgkin disease</keyword>
	<keyword>non-Hodgkins Lymphoma</keyword>
	<keyword>bone marrow transplant</keyword>
</DOC>